Overall, in vitro analyses demonstrated that the expression of SOX9 is aberrantly silenced by CpG island promoter hypermethylation in bladder cancer, observations especially supported by AZA reactivation analyses. The gene discussed is SOX9; the disease is urinary bladder cancer.